Login / register
Bladder cancer is an age-old cancer that is the second most common cancer among the various urological cancers. Most NMIBC patients was treated surgery or chemotherapy and survival rate after 5 years are high. However, 20-50% of patients treated with chemotherapy continue to experience recurrence even after surgery. Previously, we focused on finding E2F1, is biomarker for predicting cancer progression and prognosis, potential for recurrence, and performing functional analysis. This confirms that E2F1 is associated RAD54L selected form the list of DNA repair-related to E2F1. RAD54L regulated by E2F1 was identified in bladder cancer cell lines as one of the factors involved only in representative HRR progress. E2F1 binds to the RAD54L promoter region through luciferase and ChIP assay to regulate the promoter activity. In addition, HR and comet assay have demonstrated that E2F1 increases the HR activity of RAD54L. Immunohistochemistry was carried out to analyze the clinical of E2F1 and RAD54L protein expressions in human bladder cancer specimens. These results suggest that RAD54L may play an important role in the prediction of bladder cancer progression by E2F1 increasing HR activity.